Back to Clinical Trials

Clinical Trials: Neurology & Clinical Neurophysiology


Source: Shire
The purpose of this clinical study is to evaluate the clinical effect of midodrine hydrochloride (ProAmatine®) compared to placebo in patients with orthostatic hypotension by measuring the time to onset of near syncopal symptoms and assessing several cardiovascular measurements, such as heart rate, blood pressure, and ECG, using the tilt table test. Read More
Last Updated: 04 May 2015
Source: Teva Pharmaceutical Industries
Primary objective of this study is to evaluate the safety of treatment with modafinil film-coated tablet. Read More
Last Updated: 24 Jul 2012
Source: Eisai Inc.
The primary objective of this study is to evaluate the effect of rufinamide on total partial seizure frequency in adolescent and adult patients with refractory partial onset seizures currently inadequately treated with a maximum of three stable antiepileptic medications. Secondary objectives are to evaluate the effect of rufinamide on secondary and exploratory outcomes, to confirm the safety profile of rufinamide, and to assess the relationship between ... Read More
Last Updated: 01 Jan 2013
Source: Sunovion
This is an 18-week, double-blind, multicenter study with gradual conversion from previous antiepileptic therapy to eslicarbazepine acetate monotherapy in subjects with partial epilepsy. Read More
Last Updated: 12 Sep 2016
Source: Sunovion
This is a long term, open-label, safety extension study in subjects with partial onset seizures. Read More
Last Updated: 02 Jan 2017
Source: Jazz Pharmaceuticals
This is a Phase 3 study to assess the long-term safety and maintenance of efficacy of JZP-110 in subjects who have completed Study 14-002, 14-003, 14-004, 15-004, 15-005, ADX-N05 201, or ADX-N05 202. Read More
Last Updated: 29 Nov 2016
Source: Pharnext SA
The purpose of this study is to determine whether PXT3003 is effective and safe in the treatment of Charcot-Marie-Tooth disease - Type 1 A (CMT1A). This double-blind study will assess in parallel groups 2 doses of PXT3003 compared to Placebo in CMT1A patients treated for 15 months. Read More
Last Updated: 03 Jan 2017
Source: National Institutes of Health Clinical Center (CC)
The purpose of this study is to assist training doctors about different diseases of the nervous system affecting sleep. Patients selected to participate in this study will have any of a variety of sleep disorders. They will undergo several tests including an overnight recording of brain activity, eye movement, leg movement, breathing, heart rate, and other measures. Results of these tests will be used to better understand diseases causing sleep disorders ... Read More
Last Updated: 23 Jan 2017
Source: Pharnext SA
All randomised patients with Charcot-Marie-Tooth Type 1A (CMT1A) who completed the primary study CLN-PXT3003-02, i.e. 15-month double-blind treatment with PXT3003 or placebo, will be eligible to continue in the extension study CLN-PXT3003-03. Patients randomised to PXT3003 dose 1 or 2 in the primary study (CLN-PXT3003-02) will continue in the extension study at the same dose, while the patients who received placebo will be assigned to one of the two active ... Read More
Last Updated: 24 Jan 2017
Source: MEDA Pharma GmbH & Co. KG
To assess clinical efficacy and safety of long-term orally administered thioctic acid in the treatment of diabetic polyneuropathy. Read More
Last Updated: 28 Nov 2016
Source: Teesside University
The effect of a 70 minute Pain Neurophysiology Education session on Sport Therapy Students Knowledge, Attitudes and Clinical Behaviour Towards Athletes With Chronic Pain Read More
Last Updated: 21 Dec 2016
Source: Midnight Pharma, LLC
The aim of the study is to determine the minimum effective dose of ACT-078573 on sleep efficiency and to assess the effects of different doses of ACT-078573 on other PSG parameters. Read More
Last Updated: 10 Feb 2016
Source: Jazz Pharmaceuticals
This trial is a 12 week, randomized, double-blind, placebo controlled, multicenter, 5-arm parallel group study of safety and efficacy of JZP-110 in the treatment of excessive sleepiness in adult subjects with OSA. Read More
Last Updated: 05 Sep 2016
Source: Ipsen
The purpose of the study is to document long-term response in real-life practice after injection cycles with BoNT-A in subjects suffering from idiopathic cervical dystonia (Long-term clinical and pharmaco-economic data). Read More
Last Updated: 29 Sep 2016
Source: Jazz Pharmaceuticals
This trial is a 12-week, randomized, double-blind, placebo controlled, multicenter, 4-treatment parallel group study of the safety and efficacy of JZP-110 in the treatment of excessive sleepiness in adult subjects with narcolepsy. Read More
Last Updated: 29 Nov 2016
Source: Sheffield Teaching Hospitals NHS Foundation Trust
This is a non-invasive study investigating whether EEG, which is used in routine clinical care can be useful in diagnosing dementia. Novel in house developed software will analyse EEG data for this purpose from people with Alzheimer's disease and healthy volunteers. Read More
Last Updated: 20 Apr 2015
Source: Teva Pharmaceutical Industries
The purpose of this study is to evaluate the continued efficacy of modafinil treatment, compared to placebo treatment, in children and adolescents with attention-deficit/hyperactivity disorder (ADHD) who are responders to modafinil treatment. Read More
Last Updated: 07 May 2014
Source: Aveiro University
This study compared the effectiveness of pain neurophysiology education and neck/shoulder exercises with no intervention in adolescents with chronic idiopathic neck pain (CINP). Read More
Last Updated: 05 Jul 2016
Source: VA Office of Research and Development
In this study, the investigators are looking at how PTSD affects things such as memory, attention, reaction to sounds, eye movements, and heart rate. The investigators are also studying whether a medication called prazosin has an effect on these things. Read More
Last Updated: 19 Sep 2013
Source: Midnight Pharma, LLC
A polysomnography study to evaluate the effect, safety and tolerability of oral administration of almorexant (ACT 078573) in adult subjects with primary insomnia. Read More
Last Updated: 10 Feb 2016
Page 1 of 50